Telehealth Weight Loss/GLP-1 Prescribing: What Psychiatrists Can Do in Michigan

If you’re a psychiatrist or PMHNP watching the GLP-1 revolution unfold, you’ve probably asked yourself: ‘Should I be prescribing these medications? Is it even within my scope?’

Here’s the short answer: Yes, psychiatrists can prescribe weight loss medications, including GLP-1 agonists like semaglutide and tirzepatide. You have full prescriptive authority in all 50 states. For PMHNPs, the answer is more nuanced—it depends on your state’s scope of practice laws and whether you have physician collaboration in place.

But the real questions are: Should you? And more importantly, how do you do it compliantly while building a sustainable practice?

This guide breaks down the regulatory landscape, economic realities, and practical considerations for psychiatric providers entering the weight management space—whether you’re adding GLP-1s to your existing psych practice or considering a dedicated weight loss service line.

Why Psychiatrists Are Uniquely Positioned for Weight Management

Let’s address the elephant in the room: ‘Isn’t weight loss outside my specialty?’

Not really. Here’s why psychiatrists are actually well-suited for this work:

Your patients need it. Many psychiatric medications—especially atypical antipsychotics—cause significant weight gain. If you’re prescribing olanzapine or quetiapine, you’re already managing the metabolic fallout. Adding a GLP-1 isn’t ‘scope creep’—it’s comprehensive care.

Mental health and metabolic health are linked. Obesity exacerbates depression and anxiety. Depression worsens obesity. You can’t treat one without acknowledging the other. GLP-1s have shown potential benefits for mood, impulse control, and even substance use disorders—areas psychiatrists understand better than most medical specialties.

You’re already monitoring metabolic markers. Psychiatrists routinely check glucose, lipids, and weight for patients on psych meds. You’re not starting from zero—you’re expanding what you already do.

The evidence is strong on psychiatric safety. Early concerns about GLP-1s causing depression or suicidality have been debunked. A 2025 meta-analysis found no increase in depression or suicidal ideation with GLP-1 medications compared to placebo—in fact, treated patients showed slightly lower rates of depressive symptoms. The FDA and EMA reviewed the data and found no causal link to psychiatric adverse events.

As one obesity medicine-certified psychiatrist put it: ‘If we truly understand that these systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’

That said, competence matters. If you’re going to prescribe for weight management, invest in training—whether that’s CME courses in obesity medicine, mentorship from endocrinologists, or pursuing board certification through the American Board of Obesity Medicine (yes, psychiatrists are eligible).

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

The Regulatory Reality: What You Need to Know

For Psychiatrists (MD/DO)

You have full prescriptive authority. No additional certification is required to prescribe FDA-approved weight-loss medications or off-label GLP-1s (though some states like Mississippi have restricted off-label use—more on that below).

What you must do:

• Establish a valid patient relationship (telehealth video consults count in most states)
• Document appropriate indications (typically BMI ≥30, or ≥27 with comorbidities)
• Follow state-specific prescribing protocols where they exist
• Check Prescription Drug Monitoring Programs (PDMPs) before prescribing controlled substances like phentermine

Where it gets tricky:Some states impose additional requirements for weight-loss prescribing—even for physicians. For example:

• Florida requires an initial comprehensive exam (can be telehealth), documented BMI criteria, written informed consent, and follow-ups at least every 3 months. Patients must receive the state’s ‘Weight-Loss Consumer Bill of Rights.’

• New Jersey mandates comprehensive workup including psychiatric assessment, nutritional counseling recommendations, and regular monitoring.

• Virginia requires monthly follow-ups for the first several months and documentation of a diet/exercise plan.

These aren’t suggestions—they’re board rules. Violate them and you risk licensure action.

For PMHNPs

Your prescribing authority depends entirely on your state’s scope of practice laws. Here’s the breakdown:

Full Practice Authority (FPA) States (~24 states + DC): You can prescribe weight-loss medications independently after meeting experience requirements. Examples include Arizona, Colorado, Hawaii, Maryland, Montana, Nevada, New Mexico, Oregon, Washington, Alaska, Connecticut, Maine, New Hampshire, Rhode Island, Vermont, Wyoming, and Illinois (after 4,000 hours and 250 CE hours).

Reduced Practice States (~14 states): You need a collaborative agreement with a physician for prescribing, but not for all practice activities. Examples include New York (independent after 3,600 hours), Pennsylvania (collaboration required for prescribing), Kansas, Massachusetts, Nebraska, Oklahoma, Tennessee, West Virginia.

Restricted Practice States (~12 states): You must practice under physician supervision or delegation. This includes Texas, Florida, California (transitioning to FPA by 2026), North Carolina, South Carolina, Alabama, Georgia, Missouri, Louisiana.

Critical caveat: Even in FPA states, some insurers and pharmacies may push back on NP-prescribed GLP-1s without physician involvement—not because it’s illegal, but because of internal policies or prior authorization requirements. Having a physician medical director can smooth these friction points.

Specialty scope consideration: As a PMHNP, your training focused on psychiatric care, not metabolic medicine. While you can expand your scope with additional training, be prepared to demonstrate competency if questioned. Many psychiatric NPs limit weight-loss prescribing to patients already under their psychiatric care (treating both depression and obesity), which keeps it clearly within an integrated care model.

State-by-State Snapshot: What You Need to Know

Here’s a quick reference for the six highest-volume states:

California

• NPs: Transitioning to independence via AB 890; full independent practice starts Jan 2026, but Corporate Practice of Medicine rules still require physician oversight of clinic operations
• Prescribing: Psychiatrists unrestricted; NPs need standardized procedures now, full authority coming
• Telehealth: Wide open; no controlled substance restrictions beyond federal law
• Parity: Yes—commercial insurers must reimburse telehealth equally

Texas

• NPs: Must have Prescriptive Authority Agreement with TX physician; monthly quality reviews required
• Prescribing: Psychiatrists unrestricted (except Schedule II stimulants for weight loss are banned); NPs prescribe under delegation only
• Telehealth: Allowed; must check PMP for controlled substances
• Corporate Practice: Strong—physician oversight required for clinics
• Parity: Coverage parity exists; payment parity still being pushed for private insurance

Florida

• NPs: Must have physician protocol; even ‘autonomous’ NPs (primary care only) can’t independently prescribe controlled substances
• Prescribing: Strict rules—BMI documentation, informed consent, 3-month follow-ups mandatory for all providers
• Telehealth: Cannot prescribe controlled substances via telehealth (phentermine is out unless there’s a psychiatric exception); GLP-1s (non-controlled) are fine
• Enforcement: High scrutiny—Board actively investigates weight loss clinics
• Clinic licensing: Health Care Clinic Act applies—must have FL physician medical director

New York

• NPs: Independent after 3,600 hours; can prescribe including controlled substances
• Prescribing: No special state obesity rules; follow standard of care and check I-STOP PMP for controlled meds
• Telehealth: Fully supported; payment parity since 2022
• Opportunity: Large market, especially NYC, with sophisticated patients seeking integrated care

Pennsylvania

• NPs: Collaboration required; physician’s name must appear on prescriptions alongside NP’s
• Prescribing: Standard medical practice rules apply; no unique obesity regulations
• Telehealth: Open but lacks comprehensive parity statute (tele-mental health has parity via Act 69)
• FPA outlook: Bills introduced but not passed—collaboration likely to continue

Illinois

• NPs: Can achieve Full Practice Authority after 4,000 hours + 250 CE hours; most progressive Midwest state
• Prescribing: FPA-NPs can prescribe controlled substances (with some Schedule II consulting requirements first year)
• Telehealth: Strong parity laws; IL Medicaid reimburses APRNs at 100% of physician rates
• Opportunity: Mix of urban and underserved rural areas; good reimbursement environment

The Telehealth Question: Can You Prescribe Remotely?

Short answer: Usually yes, but with critical state-level exceptions.

Federal law: The DEA has extended COVID-era waivers through December 31, 2025 (likely to be extended further), allowing providers to prescribe controlled substances via telehealth without an initial in-person exam. This covers phentermine (Schedule IV).

But state law can override federal permissions. Here are the landmines:

Florida: Bans controlled substance prescribing via telehealth except for psychiatric treatment, inpatient/hospice care, or acute pain. Weight loss isn’t listed. You cannot prescribe phentermine via telehealth to Florida patients. GLP-1s (non-controlled) are fine.

Alabama: Requires initial in-person exam for controlled substance prescribing—no pure telehealth start for phentermine.

About 8 states have stricter-than-federal telehealth controlled substance rules. Most states (~42) align with federal flexibility.

Best practice: Use video consultations (not just questionnaires) for initial visits. Document thoroughly—weight, vital signs (even if patient self-reports), medical history, informed consent. Schedule regular follow-ups per state requirements (every 3 months in Florida, monthly initially in Virginia).

Economics: What Does It Actually Cost to Acquire Weight-Loss Patients?

Let’s talk money—because this is where most content gets it wrong.

The DIY marketing myth: Many articles claim you can acquire psychiatric or weight-loss patients for ‘$30-50 per lead’ through Google Ads or SEO. This is dangerously misleading.

Here’s the reality of patient acquisition costs when you’re doing it yourself:

Google Ads for mental health or weight loss:

• Cost per click: $15-40+ (highly competitive keywords)
• Conversion rate: 2-5% (most clicks don’t book)
• Realistic cost per booked patient: $200-400+
• That’s before factoring in no-shows, unqualified leads, or patients who book but never start treatment

SEO (building organic search traffic):

• Time to results: 6-12 months of consistent investment
• Monthly costs: $2,000-5,000 (content creation, technical SEO, link building)
• Most solo providers lack the expertise and stamina for this

Directory listings (Psychology Today, Zocdoc):

• Monthly fees: $30-100+ (just to be listed)
• You compete with hundreds of other providers on the same page
• Zocdoc charges $35-100+ per booking on top of subscription fees
• Total monthly cost can hit $500-1,500 with uncertain ROI

The hidden costs everyone ignores:

• Staff time to handle inquiries and qualify leads
• Failed campaigns that don’t convert
• Testing and optimization (burning ad spend to figure out what works)
• Opportunity cost of your time learning marketing instead of seeing patients

Real math: If you’re spending $3,000-5,000/month on marketing (agency fees + ad spend + directories + your time), and you acquire 10-15 new patients, your actual cost per patient is $200-500. Many months you’ll acquire fewer. Some campaigns will fail entirely.

Where platforms like Klarity fit: Instead of gambling on marketing channels, Klarity uses a pay-per-appointment model—you pay a standard fee only when a qualified patient books with you. No upfront spend. No monthly subscriptions. No wasted ad dollars.

The value proposition is simple:

• Pre-qualified patients already matched to your specialty and availability
• No patient acquisition risk—you only pay when you see patients
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule—see as many or as few patients as you want

Think of it this way: if you’re currently spending $4,000/month on marketing hoping to land 12-20 new patients (your actual results may be lower), versus paying a per-patient fee for 20-30 guaranteed appointments, which has better ROI?

For most providers—especially those starting out, scaling up, or who simply want to practice medicine instead of becoming marketing experts—the platform model removes all acquisition risk.

Reimbursement: Can You Actually Get Paid?

The short answer: Yes, and coverage is expanding rapidly.

Insurance Coverage for GLP-1s

Most major insurers now cover FDA-approved weight-loss medications (Wegovy, Saxenda, Zepbound) with prior authorization. Typical requirements:

• BMI ≥30, or ≥27 with comorbidity (diabetes, hypertension, etc.)
• Documentation of lifestyle modification attempts
• Often limited to 30-day initial supply to monitor adherence

Medicare coverage: As of late 2025, Medicare announced it will begin covering anti-obesity medications—a massive shift that opens treatment to millions of seniors. Implementation rolling out through 2026.

Medicaid: Varies by state; coverage expanding following Medicare’s lead.

Billing for Your Services

Visit reimbursement:

• Use standard E/M codes (99202-99215) or psychiatric evaluation codes
• Initial evaluations: ~$150-200 (Medicare)
• 15-20 minute medication management follow-ups: $75-120
• Telehealth pays at parity in most states (CA, NY, IL, PA, and Medicare)

Psychiatrists vs. NPs:

• MDs: 100% of physician fee schedule
• NPs: 85-100% depending on payer (Illinois Medicaid pays NPs at 100%)

Prior authorization tips:

• Document BMI and comorbidities clearly
• Note previous weight loss attempts (diet, exercise programs)
• Include mental health comorbidities if relevant (depression, binge eating)
• Some insurers want to see you’re coordinating or providing lifestyle counseling—document your recommendations

Cash-pay alternative: Many patients still pay out-of-pocket due to insurance hassles or coverage gaps. Typical cash fees: $100-200 for initial consult, $50-100 for follow-ups. Some providers charge monthly memberships ($99-199/month) that include visits and medication coordination.

Controlled Substances: The Phentermine Problem

Phentermine (Schedule IV) is one of the most commonly prescribed weight-loss medications—it’s cheap, effective short-term, and patients often request it.

The challenge: Phentermine is a controlled substance, which means:

• Federal DEA registration required
• State PDMP checks mandatory before each prescription
• Some states ban telehealth prescribing of controlled substances (Florida, Alabama)
• Higher regulatory scrutiny

Risk management:

• Only prescribe for FDA-approved indications (BMI ≥30 or ≥27 + comorbidity)
• Limit duration (typically 12 weeks per FDA labeling; some extend with monitoring)
• Document cardiovascular screening (phentermine is contraindicated in uncontrolled hypertension, heart disease)
• Monitor for abuse potential (rare but possible)
• Check PDMP religiously—document in chart

Alternative approach: Many telehealth providers focus exclusively on non-controlled GLP-1 agonists (semaglutide, tirzepatide, liraglutide) to avoid controlled substance regulations entirely. These are more expensive but have better long-term efficacy, fewer legal headaches, and broader insurance coverage.

Practical Implementation: How to Add Weight Management to Your Practice

Step 1: Get Trained

• Complete CME in obesity medicine (60+ hours available through Obesity Medicine Association)
• Consider ABOM certification if you’re serious about this as a service line
• Learn GLP-1 dosing protocols, side effect management, and contraindications
• Understand compounding issues (avoid non-FDA-approved salt forms)

Step 2: Check Your State’s Rules

• Review your state medical/nursing board’s weight-loss prescribing guidelines
• If you’re an NP, confirm your collaborative agreement covers weight management (or obtain FPA if eligible)
• Verify telehealth controlled substance rules if prescribing phentermine
• Register with state PDMP if required

Step 3: Set Up Compliant Workflows

• Intake forms that calculate BMI and document comorbidities
• Informed consent templates (especially important in Florida, New Jersey)
• Follow-up scheduling that meets state requirements (3 months in FL, monthly in VA)
• Lab ordering (baseline metabolic panel, A1C, lipids, TSH)
• PDMP checking process integrated into prescribing workflow

Step 4: Decide on Your Model

Option A: Integrated care (my recommendation for psychiatrists)

• Add weight management for existing psych patients struggling with medication-induced weight gain or comorbid obesity
• Bill as part of comprehensive psychiatric care
• Emphasize the mental health-metabolic health connection
• Lower marketing costs since you’re serving current patient panel

Option B: Dedicated weight loss service

• Build a separate patient population seeking weight management
• Requires more marketing investment (or platform partnership)
• Higher volume potential but more regulatory scrutiny
• May need physician medical director if you’re an NP in restricted state

Option C: Platform partnership (like Klarity)

• Skip the patient acquisition entirely
• See patients on-demand via established telehealth infrastructure
• Platform handles credentialing, billing, compliance frameworks
• You focus purely on clinical care
• Pay per appointment vs. upfront marketing gamble

Step 5: Insurance Credentialing

• If billing insurance, get credentialed with major payers in your state
• Understand each payer’s prior authorization requirements for GLP-1s
• Set up billing codes (E/M primarily, possibly G0447 for obesity counseling)
• Decide whether to accept Medicaid (good coverage in some states like IL)

Common Questions from Providers

‘Will prescribing weight loss meds hurt my reputation as a psychiatrist?’

Only if you do it poorly. If you’re prescribing as part of integrated, evidence-based care—especially for patients with psychiatric comorbidities—it strengthens your reputation as a comprehensive provider. If you’re running a ‘pill mill’ aesthetic clinic with no psychiatric care, yes, that’s a problem.

The key: Frame it as metabolic psychiatry, not cosmetic medicine.

‘What if a patient has a bad outcome?’

Document obsessively. Informed consent, contraindications reviewed, side effects discussed, follow-up scheduled. If you meet the standard of care and document it, you’re defensible. The risk isn’t higher than prescribing antipsychotics—arguably lower.

GLP-1s have an excellent safety profile. Most common side effects are GI (nausea, constipation, diarrhea)—manageable with dose titration. Serious adverse events (pancreatitis, gallbladder issues) are rare and manageable with proper screening.

‘Do I need malpractice insurance coverage for weight loss prescribing?’

Check with your carrier. Most psychiatric malpractice policies cover any prescribing within your license scope, but if you’re doing high-volume weight loss as a separate business line, get confirmation in writing. Some carriers may want a rider.

‘Can I prescribe GLP-1s off-label?’

Yes, in most states. Off-label prescribing is legal and common (Ozempic for weight loss instead of FDA-approved Wegovy). However, Mississippi explicitly banned off-label GLP-1 prescribing for weight loss as of August 2023. Check your state.

‘What about compounded semaglutide?’

Proceed with extreme caution. FDA has warned about non-FDA-approved salt forms (semaglutide sodium) and compounding pharmacies using pharmaceutical-grade ingredients without proper registration. Alabama’s medical board explicitly prohibited using improperly sourced compounded semaglutide.

If you prescribe compounded GLP-1s:

• Ensure pharmacy is FDA-registered (503A or 503B)
• Verify they’re using FDA-sanctioned ingredients
• Understand this is higher regulatory risk than brand name
• Document medical necessity (e.g., patient can’t afford brand name)

Honestly? Unless there’s a genuine shortage or financial barrier, stick with FDA-approved products. Less liability.

‘How do I handle patients who just want the ‘Ozempic for vanity’ (BMI <27)?'

Draw the line at evidence and legality. FDA approval is for BMI ≥30 or ≥27 with comorbidity. Prescribing outside these parameters:

• Won’t be covered by insurance (patient pays out of pocket)
• Puts you at risk of board investigation if there’s a complaint
• Isn’t supported by evidence for benefit

If a patient doesn’t meet criteria, explain why and offer evidence-based alternatives (nutrition counseling, therapy for body image issues if that’s the underlying concern).

The Bottom Line: Should You Do This?

You should consider adding weight management if:

• You have patients struggling with medication-induced weight gain or obesity complicating their psychiatric care
• You’re willing to invest in training and stay current with obesity medicine guidelines
• You can navigate your state’s regulatory requirements without cutting corners
• You want to offer truly integrated mental health and metabolic care
• You’re looking for additional revenue streams and patient growth

You should not do this if:

• You’re only interested because ‘GLP-1s are hot right now’
• You’re unwilling to learn the medicine beyond ‘write for Ozempic’
• You can’t commit to proper follow-up and monitoring
• Your state’s regulations are too restrictive (Florida NPs without collaborators, for example)
• You’re not prepared for the administrative burden of insurance PAs and compliance documentation

The platform opportunity: If you want to see weight management patients without the headache of marketing, compliance frameworks, credentialing, and patient acquisition risk, partnering with a platform like Klarity makes sense. You get:

• Steady patient flow (as much as you want)
• Pre-built telehealth infrastructure
• Compliance support and protocol templates
• No upfront costs or monthly subscriptions
• Payment per appointment—guaranteed ROI

For many psychiatric providers, especially those starting out or scaling up, this removes the biggest barrier: finding qualified patients without burning $5,000/month on marketing hoping something sticks.

Ready to Explore Telehealth Weight Management?

If you’re a psychiatrist or PMHNP interested in offering weight management through a platform that handles patient acquisition, compliance infrastructure, and telehealth logistics—so you can focus on medicine—Klarity Health is built for providers like you.

What Klarity offers:

• Pre-qualified patients seeking psychiatric care and weight management
• Both insurance and cash-pay patient flow
• Flexible scheduling—work as much or as little as you want
• No marketing costs—pay only per appointment
• Credentialing and compliance support
• State-specific guidance for NPs and MDs

Join a network of psychiatric providers offering integrated care—without the risk and expense of DIY patient acquisition.

👉 Learn more about joining Klarity’s provider network (link to provider recruitment page)

FAQ: Weight Loss Prescribing for Psychiatric Providers

Q: Can psychiatric nurse practitioners prescribe GLP-1s independently?
A: It depends on your state. In full practice authority states (like Illinois, Washington, Oregon, New Mexico), yes—after meeting experience requirements. In restricted states (Texas, Florida, most of the South), you need physician collaboration. Even in FPA states, some insurers may push back without physician involvement for high-cost meds.

Q: Do I need to be board certified in obesity medicine to prescribe weight loss medications?
A: No, it’s not legally required. However, pursuing certification through the American Board of Obesity Medicine (ABOM) strengthens your scope-of-practice legitimacy, improves your clinical competence, and can differentiate your practice. Many psychiatrists are now pursuing dual certification.

Q: Can I prescribe phentermine via telehealth?
A: In most states, yes—thanks to federal DEA waivers through December 2025. However, Florida and Alabama ban controlled substance prescribing via telehealth for weight loss (Florida allows it only for psychiatric treatment). Always check your state’s specific rules and PDMP requirements.

Q: How often do I need to see weight-loss patients for follow-up?
A: It varies by state. Florida requires at least every 3 months. Virginia requires monthly visits initially, then every 30 days for the first few months. Other states follow standard medical practice (typically every 4-6 weeks for medication management). Check your state board rules.

Q: Will insurance cover GLP-1s for weight loss?
A: Increasingly, yes. Most major commercial insurers now cover FDA-approved weight-loss medications (Wegovy, Saxenda, Zepbound) with prior authorization. Requirements typically include BMI ≥30 or ≥27 with comorbidity, documentation of lifestyle modification attempts, and medical necessity. Medicare coverage is rolling out in 2026. Medicaid varies by state.

Q: What’s the difference between Ozempic and Wegovy?
A: Same active ingredient (semaglutide), different FDA approvals. Ozempic is approved for type 2 diabetes; Wegovy is approved for weight loss at a higher dose (2.4mg). Prescribing Ozempic for weight loss is off-label (legal in most states, but Mississippi banned it). Insurance typically only covers Wegovy for weight loss.

Q: What if my patient doesn’t meet BMI criteria but wants a GLP-1?
A: FDA approval is for BMI ≥30 or ≥27 with weight-related comorbidity. Prescribing outside these parameters won’t be covered by insurance and could expose you to regulatory risk if there’s a complaint. Stick to evidence-based criteria.

Q: Do I need a separate DEA license to prescribe weight loss medications?
A: You need your standard DEA registration to prescribe any controlled substances (like phentermine, which is Schedule IV). GLP-1s are not controlled and don’t require DEA registration. Most psychiatric providers already have DEA registration for Schedule II-V meds.

Q: Can I use compounded semaglutide?
A: Only if the compounding pharmacy is FDA-registered (503A or 503B) and uses pharmaceutical-grade, FDA-sanctioned ingredients. Several states (Alabama, for example) have cracked down on improper compounding. Brand-name FDA-approved products are safer from a liability standpoint.

Q: What’s the realistic revenue potential from adding weight management?
A: It varies widely. If you’re adding it to existing psychiatric practice (5-10 patients/month), expect $5,000-10,000/month additional revenue (combination of visit fees and potentially medication dispensing margins if allowed). If you’re building a dedicated weight loss practice or working with a high-volume platform, $15,000-30,000+/month is realistic for full-time equivalent work. The key variable is patient volume—which is why platforms that handle acquisition are attractive.

Q: How do I compete with endocrinologists and primary care docs who also prescribe GLP-1s?
A: Emphasize your psychiatric expertise. You understand the mental health dimensions of obesity—emotional eating, binge eating disorder, depression comorbidity, medication-induced weight gain. Many patients seeking weight management also struggle with mental health issues. Your ability to treat both simultaneously is a competitive advantage. Position yourself as offering integrated metabolic-psychiatric care, not just ‘weight loss.’

References

1. Medical Director Co. How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? 2025 Definitive Guide. Updated 2025. Available at: https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/

2. Medical Director Co. Florida Weight Loss Clinic and Telehealth Compliance Guide (2025). Updated 2025. Available at: https://www.medicaldirectorco.com/florida-weight-loss-clinic-and-telehealth-compliance-guide-2025/

3. Medical Director Co. Texas Weight Loss Clinic & Telehealth Compliance Guide (2025). Updated 2025. Available at: https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

4. Florida Administrative Code Rule 64B15-14.004 – Standards for Prescription of Obesity Drugs. Effective August 8, 2022. Available at: https://www.law.cornell.edu/regulations/florida/Fla-Admin-Code-Ann-R-64B15-14-004

5. Foley & Lardner LLP. A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs. Mondaq, July 24, 2023. Available at: https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs

6. RxAgent. Federal Permission, State Prohibition: The 2026 Telehealth Compliance Trap. December 16, 2025. Available at: https://rxagent.co/blog/telehealth-compliance-trap

7. Phillips SJ. 36th Annual APRN Legislative Update: Improving Access Through Telehealth Initiatives. The Nurse Practitioner Journal. January 2024;49(1). Available at: https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx

8. Lewis E. Should Psychiatrists Prescribe GLP-1 Medications? An Evidence-Based Perspective. DrLewis.com. January 4, 2026. Available at: https://drlewis.com/glp-1-medications-psychiatry/

9. Lewis E. GLP-1 Medications and Mental Health: Separating Facts from Myths. DrLewis.com. November 26, 2025. Available at: https://drlewis.com/glp-1-mental-health/

10. Axios. COVID-era telehealth prescribing rules extended through 2025. November 18, 2024. Available at: https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

11. Axios. Trump administration announces Medicare will cover weight-loss drugs. November 6, 2025. Available at: https://www.axios.com/2025/11/06/medicare-coverage-weight-loss-glp1-ozempic-trump

12. TheraThink. Insurance Reimbursement Rates for Psychiatrists [2026 Update]. 2026. Available at: https://therathink.com/insurance-reimbursement-rates-for-psychiatrists/

13. Blue Cross Blue Shield of Texas. Provider Notice: 30-Day Supply Limit for GLP-1 Obesity Medications. October 4, 2024. Available at: https://www.bcbstx.com/provider/education/education/news/2024/10-04-24-pharmacy-supply-limit-glp1-obesity

This guide is for informational purposes only and does not constitute legal or medical advice. Providers should consult with their state medical/nursing boards, malpractice carriers, and legal counsel regarding specific practice questions. Regulations change frequently—verify current requirements before implementing any new service line.

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting